Feng C, Tan P, Nie G, Zhu M. Biomimetic and bioinspired nano-platforms for cancer vaccine development. Exploration (Beijing, China). 2023;3(3):20210263. doi:10.1002/EXP.20210263.

Hu Z, Anandappa AJ, Sun J, et al. A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood. 2018;132(18):1911-1921. doi:10.1182/blood-2018-04-843763.

Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217-221. doi:10.1038/nature22991.

Smart AC, Margolis CA, Pimentel H, et al. Intron retention is a source of neoepitopes in cancer. Nat Biotechnol. 2018;36(11):1056-1058. doi:10.1038/nbt.4239.

Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168-182. doi:10.1038/nri.2017.131.

Ott PA, Fritsch EF, Wu CJ, Dranoff G. Vaccines and melanoma. Hematol Oncol Clin North Am. 2014;28(3):559-69. doi:10.1016/j.hoc.2014.02.008.

Rajasagi M, Shukla SA, Fritsch EF, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014;124(3):453-62. doi:10.1182/blood-2014-04-567933.

Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res. 2014;2(6):522-9. doi:10.1158/2326-6066.CIR-13-0227.

Bachireddy P, Burkhardt UE, Rajasagi M, Wu CJ. Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer. 2015;15(4):201-15. doi:10.1038/nrc3907.

Romero P, Banchereau J, Bhardwaj N, et al. The Human Vaccines Project: A roadmap for cancer vaccine development. Sci Transl Med. 2016;8(334):334ps9. doi:10.1126/scitranslmed.aaf0685.